Nespo
darbepoetin alfa
Table of contents
Overview
The marketing authorisation for Nespo has been withdrawn at the request of the marketing authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
Nespo
|
| Agency product number |
EMEA/H/C/000333
|
| Active substance |
darbepoetin alfa
|
| International non-proprietary name (INN) or common name |
darbepoetin alfa
|
| Therapeutic area (MeSH) |
|
| Anatomical therapeutic chemical (ATC) code |
B03XA02
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Dompé Biotec S.p.A.
|
| Revision |
19
|
| Date of issue of marketing authorisation valid throughout the European Union |
08/06/2001
|
| Contact address |
Via San Martino 12
I-20122 Milan Italy |
Product information
28/10/2008 Nespo - EMEA/H/C/000333 - II/0047
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antianemic preparations
Therapeutic indication
Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adults and paediatric patients.
Treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.